Escherichia coli asparaginases (EcASNase) available for the treatment of children with acute lymphoblastic leukaemia (ALL) are largely of suboptimal quality in low-middle income countries (LMIC) and contribute to inferior outcomes. The pharmacokinetics, activity, and immunogenicity of a native (EcASNase) and a PEGylated ASNase (PEG-EcASNase) were analysed. Biogeneric EcASNase 10,000 IU/m2 was administered intramuscularly every 72 hours (Cohort 1, 76 patients)…
Biogeneric native and polyethylene glycol-conjugated E. coli asparaginases for treating children with acute lymphoblastic leukaemia
medRxiv Oncology | | Datta, N., Jana, B., Goswami, S., Roy, A., Samaddar, S., Kundu, S., Gogoi, M. P., Dasgupta, B., Dutta, T., Das, N., Saha, V., Sidhu, J., Krishnan, S.
Topics: blood-cancer